Linapaz-D

COMPOSITION:

Each film-coated tablet contains

Linagliptin…………………. 5 mg

Dapagliflozin……………… 10 mg

DESCRIPTION:
Linagliptin:
Linagliptin is a potent, reversible, and selective inhibitor of the enzyme DPP-4 (Dipeptidyl peptidase-4) which is involved in the inactivation of the incretin hormones- glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These incretin hormones are rapidly degraded by the enzyme DPP-4. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose production. Linagliptin binds to DPP-4 enzyme in a reversible manner and thus leads to an increase and a prolongation of active incretin levels. Linagliptin glucose-dependently increases insulin secretion and lowers glucagon secretion thus resulting in an overall improvement in glucose homeostasis.
Dapagliflozin:
Sodium-glucose cotransporter-2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increasing urinary glucose excretion.

INDICATIONS & USAGE:
Linapaz D is a dipeptidyl peptidase-4 (DPP-4) inhibitor and SGLT2 inhibitor combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and dapagliflozin is appropriate.

DOSAGE & ADMINISTRATION:
As directed by the physician.

CONTRA-INDICATIONS:
– Moderate to severe renal impairment.
– History of serious hypersensitivity to linagliptin or hypersensitivity to dapagliflozin.